Zepbound vs Wegovy vs Ozempic: Why Comparing GLP‑1 Options Matters
How Zepbound, Wegovy, and Ozempic Differ for Weight‑Loss
A GLP‑1 comparison guide for weight loss helps you weigh efficacy, side effects, dosing, and cost before making decisions with your clinician. Clinical trials show meaningful differences in average weight loss between options; for example, tirzepatide (branded Zepbound) reported around 22.5% mean weight loss in key trials, while Semaglutide 2.4 mg (Wegovy) produced about 15% mean weight loss in STEP‑1 (Drugs.com GLP‑1 Comparison 2024). Why this matters is practical. Differences change how often you inject, which side effects you may notice, and what your out‑of‑pocket cost might be (Drugs.com GLP‑1 Comparison 2024). Safety and tolerability also vary across studies, with some reviews noting distinct GI profiles and overall risk patterns (ScienceDirect – GLP-1RAs efficacy & safety review 2024). Keeping a clear record removes guesswork. Pepio helps you log shot dates, symptoms, and weight changes so you can compare real-world results across therapies. Users of Pepio report easier clinician conversations and steadier routines.
How to Evaluate GLP‑1 Medications: Key Comparison Criteria
Use a short checklist of practical factors when running a glp-1 evaluation criteria for weight loss. These five pillars keep comparisons focused on day‑to‑day life. They help you match clinical effects to your schedule, side‑effect tolerance, and budget.
-
Efficacy measured by average % weight loss — Look at trial results and mean reductions. Semaglutide and some newer agents show larger average losses (up to ~15% in phase‑3 trials) (ScienceDirect). Example: larger average loss may mean fewer weeks to reach a milestone, but individual results vary.
-
Dosing frequency and titration complexity — Consider how often you inject and how quickly doses increase. Example: an 8–12 week titration makes the first months more complex and may require more reminders.
-
Common side‑effects and their timeline — Check reported rates and when symptoms peak. Gastrointestinal effects occur in roughly 30–60% of users and often peak in the first 4–6 weeks (NCBI Bookshelf). Example: expect more side‑effect notes early on and plan to monitor patterns closely.
-
Out‑of‑pocket cost and insurance coverage — Compare monthly and annual costs and coverage variability. Example: retail semaglutide ranges widely, and expected monthly costs affect long‑term affordability (Forbes Health).
-
How well the medication works with a GLP‑1 tracker like Pepio — Trackability matters for adherence and insight. Tools that combine dose reminders, symptom logs, and weight charts improve routine consistency and record keeping (UChicago Medicine). For many users, Pepio helps keep dose history, injection sites, and symptom timing in one place so patterns are easier to review.
-
One‑place log for dose, date, site, and symptoms
- Custom reminders
- Injection site rotation memory
- Weight and symptom trend charts
- Exportable history for clinician visits
These five criteria keep comparisons practical and personal. Use them to weigh tradeoffs between faster average weight loss, injection burden, side‑effect timing, and cost. Track what you decide and bring clear notes to your clinician. Pepio can help you keep that record organized while you follow your prescriber’s instructions. This content is for organization and self‑tracking only; always follow guidance from your clinician, prescriber, or pharmacist.
Pepio GLP‑1 Tracker: Organize Any Injection Routine
Pepio centralizes shot logging, reminders, symptom notes, weight trends, and injection‑site rotation into one place. This keeps the routine readable and reduces guesswork about what you took and when. Research on GLP‑1 therapies shows real‑world tracking helps users stay consistent and informed (UChicago Medicine). Pepio’s web tools are free, require no sign‑up, and store data in your browser; the web Next Dose Date Calculator includes a downloadable calendar export (the web tools do not provide push notifications). The free Pepio iOS app adds push reminders, persistent history that survives browser‑data clearing, site‑rotation memory, trend charts, and exportable PDF reports.
A dedicated GLP‑1 tracker helps with adherence, surfaces symptom patterns, and ties weight changes to dose history. Users report simpler preparation for follow‑ups and clearer dose histories when they log injections and weight.
- One‑place log for dose, date, site, and symptoms
- Custom reminders keep weekly shots on schedule
- Visual weight‑loss trends tied to each medication
- Exportable reports for clinician visits (PDF from the iOS app; CSV export available from the web injection tracker)
- Free web calculators support dose conversions for compounded options
Exportable reports make doctor visits easier and reduce admin overhead, turning scattered notes into a clear timeline. Users report simpler preparation for follow‑ups and cleaner dose history to share with clinicians. Pepio's approach focuses on operational clarity, not medical advice, so you can keep an accurate routine record without replacing professional guidance.
Pepio is for organization and self‑tracking only. Always follow the instructions from your clinician, prescriber, pharmacist, or medication label. To see how this works for your routine, learn more about Pepio’s approach to organizing GLP‑1 injection schedules and tracking progress.
Zepbound, Wegovy, and Ozempic: Clinical Profiles & Side‑by‑Side Table
Shot-by-shot comparisons help you decide what matters for your weight‑loss journey. Below is a concise, side‑by‑side view of efficacy, dosing, side‑effects, cost, and how tracking fits into each choice.
-
Efficacy — Zepbound: ~22.5% mean weight loss in the SURMOUNT‑1 trial; Wegovy: ~15% mean loss in STEP‑1; Ozempic: ≈5–7% at 1 mg and up to about 9–10% at 2 mg, clearly lower than Wegovy 2.4 mg (~15%) (Drugs.com GLP-1 Comparison 2024, NEJM STEP‑1 review).
-
Dosing — All are given by titrated schedules with weekly injections for the injectable options; Zepbound typically titrates up to 15 mg weekly, Wegovy up to 2.4 mg weekly, and Ozempic injectable up to 2 mg weekly (oral semaglutide is a once‑daily option at different dosing). See dosing details in the FDA label (Wegovy label).
-
Side‑effects — GI side effects are common early in titration and often improve over time; hypoglycemia risk with tirzepatide increases mainly when combined with insulin or sulfonylureas (Drugs.com GLP-1 Comparison 2024).
-
Cost — List prices vary by drug and formulation; typical 2024 retail estimates: Zepbound ≈ $1,350/month, Wegovy ≈ $1,450/month, and Ozempic injectable ≈ $950/month (oral semaglutide ≈ $1,100/month) before insurance discounts (GoodRx 2024 price guide).
-
Tracking fit — Zepbound often suits users seeking larger, faster percentage loss and combined diabetes benefits; Wegovy fits users prioritizing obesity‑indication data; Ozempic fits users focused on glycemic control. Track dose, symptoms, injection site, and weight changes to compare real‑world effects.
Actionable takeaways: Zepbound shows the largest average percent weight loss in trials, followed by Wegovy and then Ozempic. GI side effects appear across all three and are common early in titration and often improve over time (Drugs.com GLP-1 Comparison 2024).
Tracking your routine makes comparisons meaningful.
-
Log your doses and shot dates so you can review dose history and see patterns over time.
-
Track symptoms after each shot with timing and severity to keep clearer notes for clinical visits.
-
Record injection sites and rotate sites to avoid repeating the same area and to remember where you injected last.
-
Monitor weight trends alongside doses to review progress beyond single weigh‑ins.
-
Use Pepio’s calculators and titration schedules for organization and dose conversions (for self‑tracking only).
-
Export or save your shot history to prepare for clinician conversations and to bring a cleaner record to appointments.
Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, or dosing recommendations. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Which GLP‑1 Is Right for You? Use‑Case Recommendations
Start with your priorities, then match the GLP‑1 to the outcome you want. Clinical trials show clear differences in average weight loss, but personal factors matter most. For example, Zepbound produced about 22.5% average weight loss in a large trial, while Wegovy and Ozempic showed lower average losses in their respective studies (Drugs.com GLP-1 Comparison 2024). Always review options with your clinician before changing medications.
If you are a new user chasing strong early loss, consider tirzepatide (Zepbound) as a potential fit. It produced the highest mean percentage weight loss in recent trials, and high‑dose subgroups saw large reductions (Drugs.com GLP-1 Comparison 2024). For someone building a routine, Pepio helps record dose dates, symptoms, and next‑dose reminders so you can track early responses and share clean notes with your clinician.
If cost and insurance access shape your decision, Ozempic or other semaglutide formulations may be more widely available or familiar in diabetes care. Pricing and coverage vary widely, and affordability often guides practical choices (Forbes Health – GLP‑1 market statistics 2025). Users focused on budget can use Pepio to log doses and vial supply estimates to manage costs and avoid missed doses between refills.
If you prioritize an obesity indication and long trial history, Wegovy (semaglutide 2.4 mg) has extensive obesity trial data and consistent responder rates. Many users choose it for its established evidence base and predictable response rates (Drugs.com GLP-1 Comparison 2024). Keeping an organized record of dose history, injection sites, symptoms, and weight helps make follow‑up visits clearer. Use Pepio to maintain that record—log dose history, rotate injection sites, track symptoms and weight progress, and use Pepio’s calculators for compounded doses—so your notes are clean and shareable with your clinician.
Pepio is for organization and self‑tracking only. Follow your clinician’s instructions for medication choices or dose changes. Learn more about Pepio’s approach to tracking doses, symptoms, and weight progress to support your decision-making.
Choose Your GLP‑1 Confidently and Keep It Organized with Pepio
Patients and clinicians typically weigh efficacy, safety profile, dosing convenience, access/cost, and personal goals when choosing a GLP‑1. Professional groups such as the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) discuss these kinds of considerations. Choose by weighing those factors alongside your clinician’s advice. Consistent tracking makes it easier to compare options and follow the plan you agreed on.
Systematic logging can support adherence and make conversations with your clinician clearer. Keeping a record of injections, symptoms, and weight helps you see patterns and makes follow‑up visits more productive. Keep records for comparisons, clinician visits, and to judge dosing convenience and cost.
Pepio helps you keep dose history, shot dates, injection sites, symptoms, and weight progress in one place. People using Pepio can organize notes and calculators so they match instructions from their clinician or pharmacist. Pepio offers free web tools plus a free iOS app that includes push reminders and exportable PDFs for clinician visits. Learn more about Pepio’s approach to organizing GLP‑1 routines and see how simple tracking fits your goals. Pepio is for organization and self‑tracking only; always follow your clinician, prescriber, pharmacist, or medication label.